Elbit announced Dec. 7 that its board of directors in Haifa hasinstructed management to explore the possibility of spinning offits healthcare, defense and commercial business interests intoseparately run companies. Under the proposal, Elscint and the
Elbit announced Dec. 7 that its board of directors in Haifa hasinstructed management to explore the possibility of spinning offits healthcare, defense and commercial business interests intoseparately run companies.
Under the proposal, Elscint and the ultrasound assets of Diasonicsin Santa Clara, CA, Vingmed Sound A/S of Norway and Sonotron HoldingAG of Switzerland would be merged into a single company. In combination,these businesses are expected to produce more than $500 millionin sales in 1995.
In a separate development, Elbit took a step toward consolidatingits ultrasound operations in November by purchasing the ultrasound-relatedassets of Elscintec, a manufacturing and R&D group owned byElscint, a subsidiary of Elbit. The deal is worth at least $14million, according to Elbit.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.